MRNA
MRNA
US60770K1079
Moderna, Inc.
Loading chart...

Company Profile

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Latest News

Related stocks

RVMD
RVMD • United States
Revolution Medicines, Inc.
189.76 USD
40.67B USD 1Y +293.4%
REGN
REGN • United States
Regeneron Pharmaceuticals, Inc.
746.54 USD
76.86B USD 1Y +31.2%
VRTX
VRTX • United States
Vertex Pharmaceuticals Incorpor
510.08 USD
129.2B USD 1Y +19.5%
INSM
INSM • United States
Insmed Incorporated
100.6 USD
21.97B USD 1Y -37.9%
INCY
INCY • United States
Incyte Corporation
112.79 USD
22.86B USD 1Y +32.1%
RPRX
RPRX • United States
Royalty Pharma plc
56.93 USD
32.9B USD 1Y +56.1%
BBIO
BBIO • United States
BridgeBio Pharma, Inc.
65.35 USD
12.78B USD 1Y +17.6%
NUVL
NUVL • United States
Nuvalent, Inc.
123.96 USD
9.79B USD

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
104.0% p.a.
Max Drawdown (5Y)
-93.9%
Sharpe Ratio (5Y)
-0.10
Beta Factor
1.09
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Unprofitable business model: The company is currently generating net losses.
Elevated Short-Term Volatility: 3Y volatility (123.0%) is noticeably higher than the 5Y average (104.0%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (104.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -95.4% in the extended horizon.
ende